lawson
Posted - 2 days ago
$SGHT Is this the reason for yesterday's gain?: Offer of Proof Regarding the Economic Comparability of the Glaukos Settlement Agreement by Alcon Inc. U.S. District Court District of Delaware (Wilmington) CIVIL DOCKET FOR CASE #: 1:21-cv-01317-JLH-SRF Sight Sciences, Inc. v. Ivantis, Inc.
Stock_Titan
Posted - 6 days ago
$SGHT Sight Sciences to Report First Quarter Financial Results on May 2, 2024
https://www.stocktitan.net/news/SGHT/sight-sciences-to-report-first-quarter-financial-results-on-may-2-t1cjv9k2od7e.html
DonCorleone77
Posted - 2 weeks ago
$SGHT 2 of 2 - Sight Sciences publishes results from MIGS study in AJO ....OMNI technology has been cleared by the FDA for canaloplasty followed by trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma. At 24 months, high baseline IOP patients who received the outflow procedure using OMNI technology had: the greatest numerical reduction in IOP, and the greatest numerical reduction in medication use. At 24 months, low baseline IOP patients who received the outflow procedure using OMNI technology had: the greatest numerical reduction in IOP, and a statistically significantly greater mean medication use reduction compared to all other treatment groups.
DonCorleone77
Posted - 2 weeks ago
$SGHT 1 of 2 - Sight Sciences publishes results from MIGS study in AJO Sight Sciences announced the results as published in the American Journal of Ophthalmology, or AJO, International of the large scale, comparative real-world clinical outcomes study of patients treated by three minimally invasive glaucoma surgery, or MIGS, technologies. Using the American Academy of Ophthalmology IRIS Registry, this large-scale MIGS study evaluated long-term two-year post-surgical outcomes among patients with primary open-angle glaucoma, or POAG, treated with the three most commonly used FDA-approved/cleared ab interno MIGS devices in the U.S. combined with cataract surgery, as well as for cataract surgery alone. OMNI facilitates an implant-free, ab interno procedure that addresses the three primary areas of resistance in the conventional outflow pathway....
Stock_Titan
Posted - 2 weeks ago
$SGHT Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma https://www.stocktitan.net/news/SGHT/sight-sciences-announces-the-publication-of-large-scale-real-world-vji5g3k136f7.html
lawson
Posted - 2 weeks ago
$SGHT North of $6. SWEET!!! C'mon Alcon, buy SGHT and avoid a costly trial and royalties.
lawson
Posted - 2 weeks ago
$ALC $SGHT patent infringement jury selection begins pretty soon between Alcon and sight sciences. We have a good sales and efficacy history with sight sciences’ products. Seems to me that the quickest fix for Alcon’s problems is to buy sight sciences, lock, stock, and barrel. Alcon gets two great products, whatever sight sciences has in development, and they make their legal problems go away, all at once.
lawson
Posted - 2 weeks ago
$SGHT jury selection begins pretty soon between Alcon and sight sciences. We have a good sales and efficacy history with sight sciences’ products. Seems to me that the quickest fix for Alcon’s problems is to buy sight sciences, lock, stock, and barrel. Alcon gets two great products, whatever sight sciences has in development, and they make their legal problems go away, all at once.
lawson
Posted - 2 weeks ago
$SGHT Sight Sciences, Inc. v. Ivantis, Inc. Assigned to: Judge Jennifer L. Hall Referred to: Judge Sherry R. Fallon Related Case: 1:23-mc-00373-GBW-SRF Cause: 35:271 Patent Infringement Set/Reset Hearings: Jury Selection set for 4/19/2024 09:30 AM in Courtroom 6D before Judge Sherry R. Fallon. A 5-day Jury Trial is reset for 4/22/2024 at 09:00 AM in Courtroom 6D before Judge Jennifer L. Hall. (twk) (Entered: 04/03/2024)
lawson
Posted - 2 weeks ago
$SGHT 2011 or 2012" (id. at 40-46) is denied. The Court is unpersuaded that the experts' opinions disregard the legal requirement to consider the "date of first infringement." IT IS FURTHER ORDERED that Defendants' Daubert motion seeking to exclude "Dr. Down's and Mr. Jarosz's respective apportionment analyses" (D.I. 294 at 9-15) is DENIED. Jarosz explained how he performed his apportionment analysis, and he did not, as Defendants contend, "opine that the value of the patented technology is 83% of the per-unit economic value" of the accused product. (Id. at 9.) The apportionment opinions are grounded in evidence, and Defendants' remaining arguments about the accuracy of the opinions go more to weight, not admissibility. Ordered by Judge Jennifer L. Hall on 4/5/2024. (ceg) (Entered: 04/05/2024)
lawson
Posted - 2 weeks ago
$SGHT ORAL ORDER: At the pretrial conference, the Court took under advisement two of the parties' Daubert motions. Having now fully considered the parties' positions, IT IS ORDERED that Plaintiff's Daubert motion seeking to exclude the opinions of Dr. Becker, Dr. Iwach, and Mr. Meyer regarding non-infringing alternatives (D.I. 289 ) is DENIED for the following reasons. (1) Plaintiff's request to exclude Becker's and Iwach's opinions as "unreliable" because the experts failed to consider certain data that Plaintiff says is relevant (D.I. 291 at 32-40), is denied. The Court finds that the opinions are admissible under FRE 702, and Plaintiff can cross-examine the experts about what data they did or didnt consider. (2) Plaintiff's request to exclude Becker's and Iwach's opinions "to the extent they assume design around efforts began at any time earlier than August 2018" and Meyer's opinions because he relies on the others' opinions and because he "assum[es] a design-around start date in
insiderbuyingselling
Posted - 2 weeks ago
$SGHT new insider selling: 10123 shares. http://insiderbuyingselling.com/?t=SGHT
insiderbuyingselling
Posted - 2 weeks ago
$SGHT new insider selling: 3414 shares. http://insiderbuyingselling.com/?t=SGHT
insiderbuyingselling
Posted - 2 weeks ago
$SGHT new insider selling: 12571 shares. http://insiderbuyingselling.com/?t=SGHT
GoonKing
Posted - 3 weeks ago
$SGHT what's the take here.?
stockregion
Posted - 3 weeks ago
Revolutionizing Glaucoma and Dry Eye Treatment: Insights from Sight Sciences' Groundbreaking Clinical Trials. In the realm of ophthalmology, groundbreaking advancements are not just welcomed; they are necessary. As we navigate through the complexities of eye diseases, companies like Sight Sciences are leading the charge with innovative solutions that promise not only relief but also a renewed hope for millions globally. Recently, at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting, Sight Sciences announced results that could very well change the landscape of glaucoma and dry eye disease treatment. This post explores these pivotal findings and their implications for patients and the medical community alike. $SGHT https://stockregion.app/p/ophthalmology-company-reports-promising
RallyRaider
Posted - 3 weeks ago
$SGHT was up 30% in AH?
MakingDreamsReality
Posted - 3 weeks ago
PM mOOvers $ONMD -OneMedNet shares are trading higher after the company completed a securities purchase agreement to provide up to $4.54 million in funding. $SGHT -Sight Sciences shares are trading higher after the company announced data from studies of two of its glaucoma and dry eye technologies will be presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting. $HSDT -Helius Medical Technologies, Inc. Announces Partnership with Lovell® Government Services to Expand Reach of PoNS Therapy™ $INVE -Identiv Announces Asset Purchase Agreement with Security Solutions Provider Vitaprotech for $145 Million $GFI - Gold Fields Yesterday Announced It Started Production At Its Salares Norte Mine In Chile's Atacama Province With Pouring Of Its First Gold-Silver Dore On March 28, 2024
twilightZone1
Posted - 3 weeks ago
$SGHT above the 200 ema on the daily.
lawson
Posted - 3 weeks ago
$SGHT “In phase 1 of the SAHARA trial, we found the interventional TearCare procedure provided statistically superior and sustained improvement in tear break-up time and multiple measures of meibomian gland secretion when compared to treatment with Restasis.3 In phase 2 (cross-over) of the study, we found that a single TearCare procedure improved signs and symptoms for patients beyond what was achieved with six months of Restasis.”
lawson
Posted - 3 weeks ago
$SGHT “Long-term data is key in the selection of a surgical treatment,” said Arkadiy Yadgarov, MD, of Omni Eye Services of Atlanta, GA. “The 12-month GEMINI trial demonstrated efficacy of the OMNI procedure combined with cataract surgery for IOP and medication reduction in mild-to-moderate glaucoma.1,2 This extension of the trial shows that these positive 12-month outcomes were sustained through 36 months.”
tradingtwenty
Posted - 3 weeks ago
$SGHT has trended 53 times in the past 24 hours (based on 5 minute intervals). Latest press release on Apr 02, 2024 05:00 PM: Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase... Link: https://tradingtwenty.com/news/416163/sight-sciences-announces-the-results-of-the-three-year-prospective-gemini-trial-and-the-cross-over-phase-of-the-sahara-rct-at-the-2024-american-society-of-cataract-and-refractive-surgery-ascrs-annual-meeting
DonCorleone77
Posted - 3 weeks ago
$SGHT 2 of 2 - Sight Sciences to present GEMINI trial data at ASCRS ....Paul Badawi, CEO and co-founder of Sight Sciences stated: "In addition to our existing robust body of clinical evidence, we now have additional data showing impressive OMNI results at 36-months, which demonstrate the vital long-term element of OMNI's efficacy. We are also pleased that new TearCare data will be shared that supports the use of TearCare technology as a primary treatment for DED."
DonCorleone77
Posted - 3 weeks ago
$SGHT 1 of 2 - Sight Sciences to present GEMINI trial data at ASCRS Sight Sciences "announced that data from studies of two of its proprietary glaucoma and dry eye technologies, the OMNI Surgical System and the TearCare System, will be presented in two oral presentations and two posters at this year's ASCRS Annual meeting April 5th to 8th in Boston, MA. OMNI technology facilitates surgeons' ability to perform a comprehensive, implant-free, minimally invasive glaucoma surgical procedure in adults with primary open-angle glaucoma. TearCare technology enables a proprietary, interventional eyelid procedure for diseased meibomian glands and is intended for the application of localized heat therapy in adult patients with evaporative dry eye disease, or DED, due to meibomian gland dysfunction, when used in conjunction with manual expression of the meibomian glands...."
Will2ride1
Posted - 3 weeks ago
$SGHT when insiders buy....u buy
Will2ride1
Posted - 3 weeks ago
$SGHT bing!
MissHollandia
Posted - 3 weeks ago
$XTIA after hour movers!!!
NR1. XTIA
NR2. $ZPTA NR3. $SGHT
